SUNNYVALE, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the appointment of Dr. Colin Bier to its Corporate Advisory Board to assist in the commercialization of the LymPro Test® as an aid in the diagnosis of the Alzheimer's type. Dr. Bier brings over 35 years of clinical expertise to the Company, having participated in numerous clinical trials, including trials in Alzheimer's disease as well as having been associated with the commercialization of several diagnostic tests.
Help employers find you! Check out all the jobs and post your resume.
